Best Practices Award – Imagene
Imagene won the 2023 Technology Innovation Leadership Award in AI-based molecular testing for cancer diagnosis.

TEL AVIV, Israel, May 2, 2023 (Newswire.com)
–
Imagene, an emerging leader in the field of AI-based precision oncology, is proud to announce its win of the Frost & Sullivan 2023 Europe Technology Innovation Leadership Award in AI-based molecular testing for cancer diagnosis.

Frost & Sullivan Best Practices awards recognize companies for demonstrating outstanding achievement and superior performance in leadership and technological innovation. Imagene AI has been acknowledged for its groundbreaking technology and commitment to innovation and creativity in supporting physicians and patients.

Ashish Kaul, industry analyst at Frost & Sullivan, said, “Imagene’s AI-based molecular testing technology scales to streamline cancer care processes and needs. It accelerates cancer diagnosis via accurate, image-based, immediate biomarker profiling, overcoming existing barriers and revolutionizing the market. Frost & Sullivan anticipates rapid, widespread technology adoption.”

Imagene AI’s technology can detect a wide range of cancer biomarkers in real-time, generating immediate genomic insights from digitized biopsy images alone. By reducing the time-to-results of molecular testing from several weeks to minutes, Imagene’s AI-based solution transforms cancer diagnosis and advances precision medicine.

“We are honored to receive this prestigious award from Frost & Sullivan, which validates our dedication to delivering world-class AI-based molecular testing solutions for cancer diagnosis,” said Dean Bitan, Co-founder and CEO of Imagene. “Our mission is to provide healthcare professionals with immediate and accurate biomarker profiling, empowering them with crucial information that enables optimal navigation in the complex cancer diagnosis process. This recognition affirms our commitment to innovation and to helping cancer patients in getting the most optimal treatment medicine can offer.”

Frost & Sullivan recognizes the high value and accuracy levels of Imagene’s AI-based molecular diagnosis solution and its strategic partnerships with leading medical centers and pharmaceutical companies worldwide. Imagene’s technology also supports pharmaceutical companies’ drug research and development activities, enabling optimal patient stratification for clinical trial optimization.

With its strong overall performance and dedication for bringing value to physicians and patients, Imagene AI is poised to set new market trends and address unmet needs in cancer care. The Frost & Sullivan 2023 Europe Technology Innovation Leadership Award recognizes Imagene’s ongoing excellence and pioneering leadership role in the AI-based molecular testing for cancer diagnosis market.

About Imagene

Imagene is an emerging leader in the field of AI-based precision oncology, leveraging AI to profile, in real-time, a broad range of cancer biomarkers from a digitized biopsy image alone. Imagene’s AI-based molecular diagnostic solutions streamline cancer care processes and accelerate cancer diagnosis through precise, image-based, immediate biomarkers profiling. 

Imagene is an award-winning diverse BioMed startup with an experienced, passionate and bright team. Our success derives from our cutting-edge technology and multidisciplinary team of data scientists, biologists, software engineers, and medical experts. The company collaborates with top-tier medical centers and pharmaceutical companies worldwide. 

For more information, visit www.imagene.ai.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact Information:

Avital Rabani

Head of Marketing

[email protected]

Original Source:

Imagene Wins Frost & Sullivan’s Technology Innovation Leadership Award for Its Revolutionary AI-Based Molecular Testing for Cancer Diagnosis

From the 13th to the 15th of June, Starrag will be exhibiting at the Orthopedic Manufacturing & Technology Exposition and Conference (OMTEC) in Chicago. On Booth 447, the world’s leading machine tool manufacturer will demonstrate its expertise in this arena by showcasing the Starrag Bumotec 191neo.

Starrag’s Bumotec 191neo
Bone plate manufacturing on the Bumotec 191neo

HEBRON, Ky., May 2, 2023 (Newswire.com)
–
With 12 different variants built upon a single platform, the new Starrag Bumotec 191^neo is a multi-axis mill/turn center that introduces a world of flexible and highly productive machining solutions. At the OMTEC exhibition, the Starrag Bumotec 191^neo will be demonstrating just how flexible, productive and capable a machine it is with the one-hit production of a bone plate. Manufactured in volume throughout the medical industry, bone plates are particularly challenging to machine – but not for the Starrag Bumotec 191^neo.

For manufacturers in the medical profession, the difficulty when producing bone plates is the ability to machine and subsequently finish the plates on all six sides in a single operation whilst striving for optimized cycle times and lights-out 24/7 production. On the booth at OMTEC, the machine will feed a 1.2-inch (30 mm) diameter titanium bar into the work envelope and deploy 20 different cutting tools to 26 operations to finish machine the bone plate in under 20 minutes. The challenge, as a medical device manufacturer would appreciate, is the complex machining of a long part between two stations whilst retaining perfect synchronization. Not only does the new Starrag Bumotec 191^neo productively achieve this by machining the bone plates from bar stock in its robust work envelope, but it eradicates any requirement for secondary operations. 

The epitome of high-end machining, the Starrag Bumotec 191^neo will machine the bone plate at OMTEC in a single operation with impeccable surface finishes, leaving a part that is burr-free and free of tabs – and then delicately placing the parts into a collection receptacle for complete unmanned production. With such stringent regulations in the medical industry, machining bone plates with absolute confidence and quality conformity whilst delivering a completely automated production cell is exactly why manufacturers need to see the Starrag Bumotec 191^neo at OMTEC. 

The impressive new Starrag Bumotec 191^neo is available in four versions, the ‘P’ with vice, ‘PRM’ with a multi-purpose pickup vice, the ‘R’ with a back-working spindle and the ‘RP’ with a combined vice and back-working spindle. Providing a choice of bar capacities of 1.7, 2, 2.6 inch (42, 50 or 65 mm), manufacturers can choose one of 12 machine configurations that are all based upon the same rigid and extremely robust. 

Maintaining unparalleled thermal and performance stability during production, the Starrag Bumotec 191^neo offers a formidable level of productivity. Compared to previous models, the new machine has a new tool change system that reduces changeovers by more than 15%. The machine also has a new milling spindle with increased torque and a back-working movement that is controlled by an electric motor. This combination provides the perfect blend of high-speed cutting with the power and rigidity for increased material removal rates whilst enhancing positional control.

The high-performance Starrag spindle is fed cutting tools from its 90-position tool magazine that now has an integrated tool breakage probe to support lights-out production runs. Further advancing the automation credentials of the new machine is the option of a traditional Bumotec palletizer or a robotic, modular or custom-made automated cell that delivers true ’24/7′ production, which is only interrupted by preventive maintenance when required. If you want to optimize your productivity with a completely flexible solution that can undertake the machining of a diverse range of component types, please come and visit Booth 447 at the OMTEC show in June.

Contact Information:

Elena Schmidt-Schmiedebach

Marketing Manager North America, Canada and Mexico

[email protected]

+18593802356

Original Source:

Starrag’s New Bumotec Machine Picks Through the Bones of Complex Manufacturing